To elucidate the role played by AKT and ERK in eIF4E activation, HPV‐positive cervical cancer cells were treated with PD184352 (MEK1/2 inhibitor [29]), Palomid‐529 (mTORC1/mTORC2 inhibitor [22]), and Ribavirin (a dual inhibitor of the PI3K/AKT and MEK/ERK pathways [23]). Here, MAP2K1 is linked to cervical carcinoma.